Ardelyx, Inc.ARDXNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

globenewswire.com

First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA

WALTHAM, Mass., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the first patient has been dosed in ACCEL (ten-03-301), a Phase 3 clinical trial designed to assess the safety and efficacy of IBSRELA® (tenapanor) for the treatment of chronic idiopathic constipation (CIC) in adults.

zacks.com

All You Need to Know About Ardelyx (ARDX) Rating Upgrade to Buy

Ardelyx (ARDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

defenseworld.net

Ardelyx (NASDAQ:ARDX) Sets New 1-Year High After Analyst Upgrade

Ardelyx, Inc. (NASDAQ: ARDX - Get Free Report)'s share price reached a new 52-week high on Wednesday after Wedbush raised their price target on the stock from $16.00 to $19.00. Wedbush currently has an outperform rating on the stock. Ardelyx traded as high as $8.17 and last traded at $8.0850, with a volume of 2709575 shares

seekingalpha.com

Ardelyx: Assessment Of Acquisition Rumors

zacks.com

Strength Seen in Ardelyx (ARDX): Can Its 15.0% Jump Turn into More Strength?

Ardelyx (ARDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

seekingalpha.com

Ardelyx: IBSRELA Momentum Drives Opportunity

Ardelyx has transformed into a commercial powerhouse with two FDA-approved, first-in-class drugs, IBSRELA and XPHOZAH, driving robust revenue growth. IBSRELA's rapid uptake and projected $410–$430 million 2026 revenue, alongside a patent extension to 2041, create a durable, generational asset and significant terminal value. XPHOZAH's $100M+ annual revenue confirms unmet need in hyperphosphatemia, but its slower growth and reimbursement complexity present ongoing risk to the renal franchise.

zacks.com

Are Medical Stocks Lagging Ardelyx (ARDX) This Year?

Here is how Ardelyx (ARDX) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.

defenseworld.net

Laura Williams Sells 50,000 Shares of Ardelyx (NASDAQ:ARDX) Stock

Ardelyx, Inc. (NASDAQ: ARDX - Get Free Report) insider Laura Williams sold 50,000 shares of the business's stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $6.98, for a total value of $349,000.00. Following the sale, the insider owned 361,563 shares in the company, valued at approximately $2,523,709.74.

defenseworld.net

Ardelyx (NASDAQ:ARDX) Reaches New 52-Week High – Time to Buy?

Ardelyx, Inc. (NASDAQ: ARDX - Get Free Report) hit a new 52-week high on Friday. The stock traded as high as $7.10 and last traded at $7.00, with a volume of 15572522 shares changing hands. The stock had previously closed at $5.83. Wall Street Analysts Forecast Growth ARDX has been the subject of a number

globenewswire.com

Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook

Company achieved significant commercial progress in 2025, generating approximately $378 million in product revenue 1

zacks.com

Wall Street Analysts See a 92.12% Upside in Ardelyx (ARDX): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 92.1% in Ardelyx (ARDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

zacks.com

Ardelyx (ARDX) Moves 5.5% Higher: Will This Strength Last?

Ardelyx (ARDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

defenseworld.net

Squarepoint Ops LLC Takes $708,000 Position in Ardelyx, Inc. $ARDX

Squarepoint Ops LLC acquired a new position in shares of Ardelyx, Inc. (NASDAQ: ARDX) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 180,711 shares of the biopharmaceutical company's stock, valued at approximately $708,000. Squarepoint Ops LLC owned about 0.07% of Ardelyx

defenseworld.net

Ardelyx, Inc. (NASDAQ:ARDX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Ardelyx, Inc. (NASDAQ: ARDX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the thirteen brokerages that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, eight have issued a buy recommendation and two have assigned a

defenseworld.net

Ardelyx, Inc. (NASDAQ:ARDX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Ardelyx, Inc. (NASDAQ: ARDX - Get Free Report) have earned an average rating of "Moderate Buy" from the thirteen brokerages that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, eight have given a buy rating and two have

globenewswire.com

Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week

WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the company presented data, including results from the first real-world study of XPHOZAH, at American Society of Nephrology's Kidney Week, currently underway in Houston.

globenewswire.com

Ardelyx to Participate at the Jefferies Global Healthcare Conference in London

WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 4:30 pm GMT/11:30 am ET.

seekingalpha.com

Ardelyx: Impressive Q3 Record Growth - Why I Buy

Ardelyx (ARDX) is rated BUY, driven by strong Q3 2025 results, led by IBSRELA's explosive growth and resilient pipeline. IBSRELA revenue surged 92% YoY, offsetting XPHOZAH's Medicare-related decline; management raised 2025 guidance and outlined long-term peak sales targets. ARDX maintains a robust cash position, near-breakeven operations, and strategic patent protection, supporting ongoing commercial and pipeline development.

seekingalpha.com

Ardelyx: A Long Overdue Rally

Ardelyx shares surged on Friday after strong Q3 results and positive guidance, validating patience during previous setbacks. The company demonstrated resilience, with recent financial performance supporting what should be renewed investor confidence in ARDX. Updated analysis highlights Ardelyx's improving fundamentals and potential for further upside following the latest quarterly report.

globenewswire.com

Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference

WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that President and CEO, Mike Raab will participate in a fireside chat at the Wedbush Rewind ASN 2025 Conference on Monday, November 10, 2025 from 11:30 a.m. to 12:00 p.m. ET.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance